Page 52 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 3
8·2%
NR
part of first-line consolidation ? in young high- risk pts as 8·9% frontline or salvage
NR
15·9%
HDT+ASCT (if <60 years + disease and n=2 progressive not upfront (n=1 refractory 16·1% consolidative >1 aaIPI) disease)
NR
NR
NR
5·8% 3·5%
NR
0%
excl. crit. n=1 after ASCT upfront=
d d a a Treatment characteristics a d 24·4% intensified R-CHOP a 11·0% R-mini-CHOP 44·7% R-CHOP14 / 21·4% R-CHOP14 55·3% R-CHOP21 35·2% R-CHOP21 75·5% R-CHOP 49·3% RCHOP21 Stage First-line treatment 23·3% R-ACVBP 27·7% R-ACVBP R-CHOP21 R-CHOP14 R-ACVBP R-CHOP21 68·5% 15·1% R-CHOP14 1·4% CHOP (2012) 64·8% R-CHOP14 100% 48·9% 84·4% 56·0% 44·0% 46·6% 67·0% 59·6% 82·5% 53·6% 65·2% NR
60 (18-85) 63·0% Age median
(range) III-IV 60 (18-78·9)
65 (22-87)
55 (21-79)
55 (18-80)
56 (23-80)
(29-80)
mean 58
Safar et al retrospective 112 100% 59 (20-79) 67·0% 81·3% 50·9% R-CHOP21 DLBCL
100%
100%
Patient characteristics
88 100%
114 100%
45 /57 100%
patients
No. of
b
73
50
prospective 69 100%
prospective 50 100%
retrospective
retrospective
retrospective
retrospective
prospective
design
Study
47 a Study characteristics
46
Table 1 Continued
44 a 45
Gonzalez-Barca
48
49 d 50 d 51
First author,
Fuertes et al
Itti et al (2013)
et al (2013)
Lanic et al
Pregno et al
Cashen et al
Nols et al
year
(2014)
(2013)
(2012)
(2012)
(2011)
50
ASCT
RT
Male